

ANALYZED BY:

Anresco Laboratories 1375 Van Dyke Avenue, San Francisco, CA 94124 C8-0000052-LIC



DISTRIBUTOR:
Metta Medical
C11-0001250-LIC

CULTIVATOR / MANUFACTURER: Metta Medical

CDPH-10004472

Sample No.:	1105805		Sample Increments:	20
Product Name:	Level - CB 25PT2112	G Protab - 215CBG	Sample Weight / Increment (g):	1.75
Matrix		ate (Orally	Total Sample Weight (g):	35
		d Concentrate)	Date Collected:	12/17/202
Batch #:	25PT2112	15CBG	Date Received:	12/20/202
Product- Batch Size (Units): ³⁹⁸⁴		Date Reported:	12/23/202
TEST SUMMA	RY			
Cannabinoid Pro	file:	C Pass	Microbiological Screen:	Se Pass
Pesticide Residu	e Screen:	Pass	Residual Solvent Screen:	O Pass
Heavy Metal Scre	en:	O Pass	Foreign Material:	O Pass
Mycotoxin Scree	n:	Ø Pass	Water Activity:	Pass
Overall:		Ø Pass		

Cannabinoid Profile SPass

Method:	MF12D012
Instrument:	Liquid Chromatography Diode Array Detector (LC-DAD)
Limit of Detection	0.1333 mg/g
Limit of Quantification	n 0.4 mg/g

Cannabinoid	mg/g	96	mg/serving	mg/package	Status
Δ8-THC	ND	ND	ND	ND	÷
Δ9-THC	ND	ND	ND	ND	Pass
Δ9-THCA	ND	ND	ND	ND	-
THCV	ND	ND	ND	ND	<u>2</u>
THCVA	ND	ND	ND	ND	5
CBD	ND	ND	ND	ND	2
CBDA	ND	ND	ND	ND	z i
CBC	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>2</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>2</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>2</td></loq<></td></loq<>	<loq< td=""><td>2</td></loq<>	2
CBCA	ND	ND	ND	ND	-
CBDV	ND	ND	ND	ND	¥:
CBG	130 53	13.053	22.80	228.03	2
CBGA	ND	ND	ND	ND	8
CBN	ND	ND	ND	ND	<u></u>
Total THC	ND	ND	ND	ND	5)
Total CBD	ND	ND	ND	ND	2
Total Cannabinoids	130 53	13.053	22.80	228.03	
Total Active Cannabinoids	130 53	13.053	22.80	228.03	<u> </u>
Serving Weight (g)	0.1747				
Package Weight (g)	1.75				

Microbiological Screen Ø Pass

Analyte	Method	Findings	Status	
Salmonella	AOAC 2016.01	Negative/1g	Pass	
STEC	3M MDS STEC/EAE	Negative/1g	Pass	

Pesticide Residue Screen Ø Pass

Method: MF-CHEM-13

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass

Anresco Laboratori es www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1105805 Batch #: 25PT211215CBG pagel of 4 Report ID: S-3

12/22/2021

12/22/2021

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.

12/22/2021



Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0 2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0 30	ND	1.0	Pass
Cypermethrin	0.10/0 30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvous)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxanil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0 30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
			8.0	Pass
Piperonyl Butoxide Prallethrin	0.02/0.06 0.04/0.10	ND ND	0.4	Pass
			20.0	
Propiconazole Propoxur	0.02/0.06	ND ND	0.02	Pass Pass
Pyrethrins		ND	1.0	
	0.10/0 30			Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiadorprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Residual Solvent Screen 🔮 Pass

Method: USP OVI<467>

Instrument: Gas Chromatography Mass Spectrometry (GC/MS)

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0 2/0.5	ND	1	Pass
Acetone	67/200	ND	5000	Pass

Anresco Laboratori es www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1105805 Batch #: 25PT211215CBG page2 of 4

12/23/2021

Report ID: S-3

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Acetonitrile	67/200	ND	410	Pass
Benzene	0 2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0 2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0 2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	BLOQ	3000	Pass
Methylene chloride	0 2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0 2/0.5	ND	1	Pass

Heavy Metal Screen SPass

Method: MF 24E020

Instrument: Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	ND	0.5	Pass

Foreign Material Ø Pass

Method: Visual

Analyte	Findings	Limit	Status	
Sand, Soils, Cinders, and Dirt	ND	25%	Pass	
Mold	ND	25%	Pass	
Imbedded Foreign Material	ND	25%	Pass	
Insect Fragment	ND	1 per 3g	Pass	
Hair	ND	1 per 3g	Pass	
Mammalian Excreta	ND	1 per 3g	Pass	

Mycotoxin Screen Ø Pass

12/22/2021

12/21/2021

12/22/2021

Method: MF-CHEM-13

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	2/5	ND	-	(*)
Afalatoxin B2	2/5	ND	2	3125
Aflatoxin G1	2/5	ND	5	-
Aflatoxin G2	2/5	ND	÷	1 - 1
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/20	ND	20	Pass
Vater Activity				12/20/2021

Water Activity

MF 14G051 Method: Instrument: Decagon

Analyte	Findings	Limit	Status	
Water Activity	0 38	0 85	Pass	

Sample #: 1105805 Batch #: 25PT211215CBG

page of 4 Report ID: S-3

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



() = Not Tested, ND = None Detected, <LOQ = Below Limit of Quantitation, LOD = Limit of Detection

Scan to verify

All LQC samples were performed and met the prescribed acceptance criteria in 16 CCR section 5730, pursuant to 16 CCR section 5726(e)(13)





Vu Lam Lab Co Director December 23, 2021

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.